.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The five-year STAMPEDE follow-up compared intensive medical and lifestyle therapy with bariatric surgical procedures in patients with type 2 diabetes and obesity. The study showed that surgery provided more durable improvement in glycemic control and greater reductions in diabetes medication use than medical therapy alone. Importantly, the benefit persisted over several years rather than being limited to the early postoperative period. The trial helped establish metabolic surgery as more than a weight-loss intervention: in selected patients, it can substantially change the course of type 2 diabetes. For surgeons, the key message is patient selection and multidisciplinary follow-up. Surgical eligibility, nutritional monitoring, diabetes medication adjustment and long-term metabolic surveillance all matter. The study does not mean surgery replaces medical care for every patient with obesity and diabetes; rather, it provides randomized evidence that metabolic surgery can deliver durable disease-modifying benefits in appropriate candidates. These findings should be incorporated into discussions with endocrinology, internal medicine and bariatric teams when considering treatment pathways for patients with difficult-to-control diabetes.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The five-year STAMPEDE follow-up compared intensive medical and lifestyle therapy with bariatric surgical procedures in patients with type 2 diabetes and obesity. The study showed that surgery provided more durable improvement in glycemic control and greater reductions in diabetes medication use than medical therapy alone. Importantly, the benefit persisted over several years rather than being limited to the early postoperative period. The trial helped establish metabolic surgery as more than a weight-loss intervention: in selected patients, it can substantially change the course of type 2 diabetes. For surgeons, the key message is patient selection and multidisciplinary follow-up. Surgical eligibility, nutritional monitoring, diabetes medication adjustment and long-term metabolic surveillance all matter. The study does not mean surgery replaces medical care for every patient with obesity and diabetes; rather, it provides randomized evidence that metabolic surgery can deliver durable disease-modifying benefits in appropriate candidates. These findings should be incorporated into discussions with endocrinology, internal medicine and bariatric teams when considering treatment pathways for patients with difficult-to-control diabetes.
Yesterday
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
